Q-omics provides the consensus-scored MIR93 profile across patient tissues and cancer cell-line models. MIR93 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MIR93 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, MIR93 RNA expression shows 13,984 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, BRCA, and UVM as cancer lineages where MIR93 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR93 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR93 survival associations across molecular data types. MIR93 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR93 RNA expression–survival associations across cancer types. High MIR93 expression shows unfavorable associations in ACC, CESC and COAD, but favorable associations in PAAD, BLCA and HNSC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MIR93 RNA expression.
This table summarizes MIR93 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR93. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR93 shows lower tumor expression in BRCA, KICH and KIRP and higher tumor expression in CHOL, STAD and COAD. The BRCA box plot shows higher MIR93 RNA expression in normal versus tumor tissue (log2 FC = −0.502, t-test p < 0.001).
This table shows molecular features associated with MIR93 in patient tissues and cancer cell lines. In patient samples, MIR93 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
